Market revenue in 2023 | USD 11,411.1 million |
Market revenue in 2030 | USD 14,078.1 million |
Growth rate | 3% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 62.28% in 2023. Horizon Databook has segmented the U.S. inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. IBD market is observing a major shift in dynamics, wherein doctors are increasingly preferring the usage of newly launched products by companies such as AbbVie and Bristol Myers Squibb over other conventional therapies.
The prescription patterns is witnessing a considerable shift with the entry of Skyrizi (in June 2022) and Zeposia (in May 2022). U.S.-based companies, such as Prometheus Biosciences and Pfizer, are providing positive Phase II stage clinical trial results for their products PRA023 (results announced in December 2022) and RVT3101 (result announced in January 2023), respectively.
The growing competition between the two companies is anticipated to provide better treatment options to patients in the upcoming years and boost =IBD market growth. Initiatives undertaken by various organizations to address the challenges in IBD research are expected to boost market growth over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account